CDK5 Inhibitory Peptides Targeting p25 While Preserving Basal Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's and frontotemporal dementia fail to address memory loss and cognitive impairment effectively, and existing CDK5 inhibitors cause significant side effects by disrupting basal CDK5 activity.
Innovation Solution
Development of CDK5 inhibitory peptides that selectively block the interaction of CDK5 with p25/p35 without affecting basal CDK5 activity or interacting with other CDKs, administered with a pharmaceutically acceptable carrier, potentially combined with additional therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CDK5 inhibitors are used to reduce CDK5 kinase activity, then neurodegenerative disorder symptoms are improved, but significant side effects occur due to disruption of basal CDK5 activity
Solution Approach 1:
The patent applies local quality by designing a peptide that specifically targets the p25-CDK5 interaction interface without affecting other CDK family members. The peptide sequence (ARAFGIPVRCYS) is engineered to match the p25 binding region of CDK5, providing selective inhibition of pathological CDK5 activity while preserving basal functions mediated by p35-CDK5 and other CDKs.
Solution Approach 2:
The invention uses a peptide molecule as an intermediary that selectively binds to the p25-CDK5 complex to prevent their pathological interaction. This peptide mediator disrupts the harmful p25-CDK5 binding without directly inhibiting CDK5 catalytic activity, thereby achieving therapeutic effects while avoiding side effects associated with broad CDK5 inhibition.
2Reliability
If CDK5 activity is inhibited to prevent neuronal death and improve cognitive function, then neurodegenerative disease progression is slowed, but basal CDK5 activity required for normal brain function is disrupted
Solution Approach 1:
The peptide inhibitor is designed with local specificity to the p25 binding epitope on CDK5. By matching the p25 sequence (ARAFGIPVRCYS), the peptide selectively interferes with p25-CDK5 binding while leaving the p35-CDK5 interaction and basal CDK5 activity intact, thus protecting against neuronal death without disrupting normal brain function.
Solution Approach 2:
The invention converts the harmful overactivity of CDK5 in neurodegenerative diseases into a therapeutic opportunity by using a peptide that mimics the protective p35 regulatory subunit. This peptide selectively neutralizes pathological p25-CDK5 interactions while preserving the beneficial basal CDK5 activity required for normal neuronal function, cognitive processes, and synaptic plasticity.
3Reliability
If broad CDK5 inhibition is used to treat neurodegenerative diseases, then neuronal death is prevented, but interaction with other CDKs and disruption of normal cellular processes occurs
Solution Approach 1:
The peptide is engineered with local specificity to the unique p25-CDK5 interaction interface. The sequence ARAFGIPVRCYS corresponds to the p25 binding region, providing high selectivity for CDK5 over other CDK family members (CDK1, CDK2, CDK4, CDK6, CDK7, CDK9, CDK11) and preventing off-target effects while maintaining effective neuronal protection.
Solution Approach 2:
The peptide acts as a selective intermediary that specifically binds to the p25-CDK5 complex without interfering with other CDK-substrate interactions. This mediator approach ensures high adaptability and selectivity, preventing neuronal death through targeted inhibition of pathological CDK5 activity while leaving other CDK-mediated cellular processes unaffected.
Data Source
AI summary
The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject a specific CDK5 peptide inhibitor and a pharmaceutically acceptable carrier.